Document Detail

Long-term clinical and hemodynamic performance of the Hancock II versus the Perimount aortic bioprostheses.
MedLine Citation:
PMID:  20837899     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The Medtronic Hancock II and the Carpentier-Edwards Perimount are among the world's most commonly used aortic bioprostheses. However, a direct comparison of their clinical performance is lacking. To minimize biases inherent to between-center comparisons, we examined these prostheses within a large, contemporary, single-center cohort. METHODS AND RESULTS: Between 1990 and 2007, 1659 patients (mean age, 73.1±9.3 years) underwent aortic valve replacement with either the Hancock II (N=1021) or the Perimount (N=638). Patients were prospectively followed-up with serial clinic visits and echocardiograms for up to 16 years (mean, 5.0±3.3 years). There was no significant difference in aortic root size preoperatively (P=0.7). Aortic root enlargement was more commonly performed with the Perimount (P<0.001), and the manufacturer valve size of the implanted prosthesis was larger with the Hancock II (P<0.001). Postoperatively, peak and mean transprosthesis gradients were higher for the Hancock II (32.7±0.7 and 16.0±0.3 mm Hg, respectively) than for the Perimount (24.9±0.7 and 13.4±0.4 mm Hg, respectively; P<0.001). However, no difference in left ventricular mass regression was observed at late follow-up (P=0.9). Unadjusted 10-year survival was 59.4%±2.4% for the Hancock II and 70.2%±3.8% for the Perimount (P=0.07). Multivariable predictors of survival did not include prosthesis type (P=0.2). CONCLUSIONS: For the same manufacturer valve size, the Perimount is larger, which may warrant enlarging the aortic root more often, and it is associated with better hemodynamics than the Hancock II. These differences do not impact survival or left ventricular mass regression, and the long-term clinical performances of the Hancock II and Perimount bioprostheses are equivalent.
Vincent Chan; Alexander Kulik; Anthony Tran; Paul Hendry; Roy Masters; Thierry G Mesana; Marc Ruel
Related Documents :
16321689 - Determinants of rapid progression of aortic root dilatation and complications in marfan...
20067609 - Losartan therapy in adults with marfan syndrome: study protocol of the multi-center ran...
17643619 - Aortic enlargement and late reoperation after repair of acute type a aortic dissection.
18154789 - Enlargement of the small aortic root during aortic valve replacement: is there a benefit?
19837529 - Short and midterm results after left subclavian artery coverage during endovascular rep...
17689749 - Usefulness of doppler echocardiography guidance during balloon aortic valvuloplasty for...
14636329 - Long-term outcome of nonsurgical candidates with medically refractory localization-rela...
1716939 - Laser therapy and insertion of wallstents for palliative treatment of esophageal carcin...
22402769 - Functional and clinical outcome of total shoulder arthroplasty with oversized glenoid.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  122     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-14     Completed Date:  2010-10-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S10-6     Citation Subset:  AIM; IM    
Division of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Aorta / physiopathology*
Aortic Diseases / mortality,  physiopathology*,  surgery*
Disease-Free Survival
Follow-Up Studies
Middle Aged
Retrospective Studies
Survival Rate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention,...
Next Document:  Development of a completely autologous valved conduit with the sinus of Valsalva using in-body tissu...